Irbesartan

This page contains recent news articles, when available, and an overview of Irbesartan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Irbesartan (when available)

Pharmacology and use:
Irbesartan, an angiotensin II receptor antagonist similar to losartan and valsartan, is used alone or with hydrochlorothiazide to treat hypertension For the treatment of hypertension.

Mechanism Of Action:
Irbesartan antagonizes angiotensin II, the primary vasoactive hormone of the renin-angiotensin system, at the AT₁ receptor subtype. As angiotensin II is vasoconstrictor which stimulates aldosterone secretion by the adrenal gland, blockage of its effects results in a decrease in systemic vascular resistance.

News Articles on Irbesartan

Plavix(R) Plus Aspirin More Effective Than Aspirin Alone in ...  -  ‎Mar 31, 2009‎
0.2% per year, RR=1.37, p=NS) ACTIVE (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) is a comprehensive program FOXBusiness

Clopidogrel plus aspirin decreases stroke risk in patients with AF ...  -  ‎Apr 14, 2009‎
In the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE)-A, 7554 patients with documented AF and with at Modern Medicine

ACTIVE (Atrial Fibrillation Clopidogrel Trial With Irbesartan for ...  -  ‎Mar 31, 2009‎
études distinctes : ACTIVE-W, ACTIVE-A et ACTIVE-I. Les études ACTIVE-A et W l'association Plavix(r)-aspirine. Aucune différence statistiquement deux Zonebourse.com

Dans la FA, ACTIVE-A montre qu'à défaut d'AVK, il faut associer le ...  -  ‎Apr 3, 2009‎
Orlando, FL, E.-U. — Après l'étude ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events), publiée en 2006 [1], theheart.org/fr

시오노기 항비만제 日서�?� 제품화  -  ‎Mar 30, 2009‎
...시오노기는 주력제품�?� 고지혈�? 치료제 '�?�레스토'(Crestor, rosuvastatin)와 고혈압치료제 '�?�베탄'(Irbetan, irbesartan)과 같�?� �?활습관병분야로 분류�?�는 항비만 디지틀보사

플�?�빅스�? 아스피린 병용 뇌졸중�?만 효과  -  ‎Apr 14, 2009‎
...임�?시험�?�ACTIVE A (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events Aspirin) 결과를 발표하고 �?�같�?� 결론내렸다. 메디칼트리뷴

혈압강하제 등 �?�약품 120개 15�?�부터 신규 보험등재  -  ‎Apr 5, 2009‎
...�?� ‘�?�화�?�베사탄정150mg(irbesartan)’, 보람제약�?� ‘�?시아정15/25mg(moexipril HCl), 한국화�?��?제약�?� ‘노바스�?�정10mg(amlodipine)’ 등 �? 16개가 추가�??다. 헬스코리아뉴스

[ACC 2009]ACTIVE-A：Clopidogrel與阿斯匹�?��?低心房纖維顫動之心血管事件  -  ‎Apr 3, 2009‎
...在「Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE)�?試驗計畫中，心房纖維顫動且有一個以上其他中風風險因素之臺灣新浪網

Treatment With Amiodarone to Prevent Atrial Fibrillation  -  ‎Mar 10, 2009‎
Patients treated with amiodarone plus irbesartan may have a lower rate of recurrence of atrial fibrillation than patients treated with amiodarone alone. Journal of American Medical Association (subscription)

Drug majors put on bid alert  -  ‎Mar 13, 2009‎
The two firms already have a partnership for the antithrombotic Plavix (clopidogrel) and the antihypertensive Avapro (irbesartan). "Overall, the most likely CITY A.M.

Office management of patients with diastolic heart failure  -  ‎Mar 4, 2009‎
A smaller randomized trial (n = 151) comparing the addition of irbesartan to standard therapy with the use of standard therapy alone found no benefit in CMAJ

Irbesartan nie poprawił rokowania u chorych z niewydolnością serca ...  -  ‎Mar 9, 2009‎
I: irbesartan po początkowo 75 mg 1 x dz., dawkę zwiększano do 300 mg 1 x dz. w ciągu 2-4 tygodni Chorzy w obu grupach otrzymywali ponadto: diuretyki (na Medycyna Praktyczna

Scompenso cardiaco con frazione d’eiezione preservata: Aprovel non ...  -  ‎Mar 3, 2009‎
I Ricercatori dello studio I-PRESERVE hanno studiato gli effetti dell’Irbesartan ( Aprovel, Karvea ) nei pazienti con questa sindrome. XagenaSalute

Sanofi-Aventis fronteggia la crisi  -  ‎Feb 24, 2009‎
...insulina glargine (+27,7%), docetaxel (+13,2%), enoxaparina sodica (+10,6%), clopidogrel bisolfato (+10,5%), irbesartan (+14,2%) e dei vaccini (+9,6%). Pharma Marketing

Ligand drug reduces hypertension in midstage study  -  Feb 2, 2009
The drug was given in either 200-milligram, 400-milligram, or 800-milligram doses and compared with placebo or 300-milligram doses of irbesartan, Forbes,

Beta-blocker benefit questioned in heart failure with preserved ...  -  Jan 9, 2009
The I-PRESERVE trial, as recently reported by heartwire, found no effect on mortality or CV events from the angiotensin-receptor blocker irbesartan (Avapro, TheHeart.Org,

Ирбе�?артан при �?ердечной недо�?таточно�?ти �? �?охранной �?и�?толиче�?кой ...  -  Feb 2, 2009
В �?той �?в�?зи было проведено крупное рандомизированное двойное �?лепое плацебо-контролируемое и�?пытание Irbesartan in Heart Failure with Preserved Ejection Medicus Amicus,

Casi un millar de nuevos EFG financiados el año pasado  -  Jan 11, 2009
...de uso hospitalario), ketorolaco trometanol (para dolor leve o moderado de uso hospitalario) y prednisona e irbesartan (de dispensación en farmacias). Correo Farmacéutico,

Irbesartan in Patients With Heart Failure and Preserved Ejection ...  -  Dec 3, 2008
Study Question: What are the effects of renin-angiotensin-aldosterone system (RAAS) blockade with irbesartan in patients with heart failure and preserved Cardiosource,

Irbesartan in Patients with Heart Failure and Preserved Ejection ...  -  Dec 3, 2008
Therefore, we studied the effects of irbesartan in patients with this syndrome. Methods We enrolled 4128 patients who were at least 60 years of age and had New England Journal of Medicine (subscription),

Treatment Fails To Improve Common Form Of Heart Failure, Study Finds  -  Dec 13, 2008
One group received 300 milligrams of irbesartan, an anti-hypertensive medication marketed as AvaproTM. The other group was given a placebo. Science Daily (press release)

B-MS to reduce workforce by an additional 10%  -  Dec 17, 2008
Plavix (clopidogrel), and other big earners such as the antipsychotic Abilify (aripiprazole) and the antihypertensive Avapro/Avalide (irbesartan). Pharma Times,

New heart research path opens  -  Dec 15, 2008
Irbesartan appeared ideal because the drug reduces the hardening of tissue and showed promising results in heart failure patients whose hearts didn't pump Charleston Post Courier,

Irbesartan in scompenso a frazione di eiezione preservata non ...  -  Dec 6, 2008
...in pazienti con insufficienza cardiaca e frazione di eiezione ventricolare sinistra preservata irbesartan non riduce significativamente gli eventi Pillole.org,

BMS, 제조시설 50% �??쇠-추가 구조조정�?� 단행  -  Dec 19, 2008
...제품�?� 항 �?�고제 프�?�빅스(clopidogrel), 정신병 치료약 �?빌리파�?� (aripiprazole) �? 고혈압 치료제 아바프로/아바�?��?�드(irbesartan) 등�?� 특허가 만료�?�다. 메디�?�뉴스,

Rasilez HCT® receives recommendation for European approval as a ...  -  21 Nov 2008
Blood Pressure Reduction Following A Simulated Missed Dose Of Aliskiren, Irbesartan, or Ramipril: A Comparative Ambulatory Blood Pressure Monitoring Study. Ad-Hoc-News (Pressemitteilung),

Rasilez HCT® receives recommendation for European approval as a ...  -  21 Nov 2008
Blood Pressure Reduction Following A Simulated Missed Dose Of Aliskiren, Irbesartan, or Ramipril: A Comparative Ambulatory Blood Pressure Monitoring Study. Edubourse.com (Communiqué de presse),

Şeker hastalığı yaygınlaşıyor  -  21 Nov 2008
...kuru ve inatçı bir öksürük, baş ağrısı, ishal, kan potasyum düzeyinde yükselme; Anjiotensin alıcı blokerleri (losartan, irbesartan, valsartan vb. Hürriyet,

Avapro Blood Pressure Drug Ineffective To Heart-Failure Patients  -  Nov 11, 2008
In the study, the participants were randomly assigned to one of two groups: some were given irbesartan, an Angiotensin II Receptor Blocker (ARB) currently eFluxMedia

American heart association conference  -  Nov 20, 2008
Use of the angiotensin receptor blocker (ARB) irbesartan does not appear to reduce mortality rates in patients with heart failure (HF), US research suggests Healthcare Republic

Irbesartan Ineffective in Treating Heart Failure With Preserved ...  -  Nov 12, 2008
By Ed Susman NEW ORLEANS -- November 12, 2008 -- There was no significant difference observed between the angiotensin receptor blocker irbesartan and DG News

Irbesartan in Heart Failure With Preserved Ejection Fraction Study ...  -  Nov 11, 2008
Accordingly, the I-PRESERVE study sought to evaluate the effect of angiotensin-receptor blockade with irbesartan on cardiovascular outcomes in these Cardiosource,

Heart Failure Patients With Normal Left Ventricular Ejection ...  -  Nov 11, 2008
The angiotensin system inhibitor irbesartan did not improve outcomes in heart failure patients with preserved left ventricular ejection fraction. MarketWatch

I-PRESERVE: Strike three for RAAS inhibition in preserved-LVEF ...  -  Nov 12, 2008
Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) is the third major prospective trial to test the effects of a drug that inhibits TheHeart.Org,

ARB ineffective in HF with preserved ejection fraction  -  Nov 11, 2008
New Orleans—The use of irbesartan for heart failure with preserved ejection fraction (HFPEF) failed to improve outcomes compared to placebo, Drug Topics Magazine,

Failed I-PRESERVE trial highlights need for new approach in heart ...  -  Nov 14, 2008
...experts say after the failure of the I-PRESERVE trial of Bristol-Myers Squibb/Sanofi-Aventis's angiotensin II receptor blocker irbesartan (Aprovel). Scrip World Pharmaceutical News (subscription),

Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):  -  Oct 31, 2008
In September 2008 , the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the authorization of a generic of irbesartan as a Earthtimes (press release),

AHA 2008: Eyes Trained on JUPITER: Cardiologists Seek Details to ...  -  Nov 5, 2008
...is devoted to heart-failure trials: of these, the I-PRESERVE study, looking at the use of irbesartan in patients with preserved ejection fraction, Medscape (registration)

Sanofi profits up as French firm rides out generic storm  -  Oct 31, 2008
Sales of the antihypertensive Aprovel/Avapro/Karvea (irbesartan) increased 14.6% to 298 million euros. The anti-obesity drug Acomplia (rimonabant), Pharma Times (registration),

Gli antagonisti recettoriali dell’angiotensina II non devono ...  -  Nov 17, 2008
I medicinali autorizzati con procedura centralizzata contenenti Irbesartan sono: Aprovel, Karvea, Irbesartan BMS e Irbesartan Winthrop. XagenaSalute,

Sartane ohne Vorteile bei diastolischer Herzinsuffizienz  -  Nov 12, 2008
Die „Irbesartan in Heart Failure with Preserved Systolic Function“ oder I-PRESERVE-Studie war die größte Therapiestudie, die bisher zu einem Sartan Deutsches Ärzteblatt,

Email & fax  -  Nov 5, 2008
...evidenze scientifiche dimostrate per le vecchie (come irbesartan) e per questo fatte percepire come analogamente efficaci ai potenziali prescrittori. La Repubblica,

RESULTATS DU TROISIEME TRIMESTRE 2008  -  Oct 31, 2008
En septembre, le CHMP a émis une opinion fa vorable à l'homologation d'un générique d'irbesartan en monothérapie en Europe. Irbesartan est protégé par un Fininfo (Communiqué de presse),

SANOFI-AVENTIS : Sanofi, Bristol : résultats décevants d'une étude ...  -  Nov 11, 2008
NOUVELLE-ORLEANS--Une vaste étude portant sur l'irbesartan, un médicament contre l'hypertension commercialisé sous le nom d'Avapro par Bristol-Myers Squibb Zonebourse.com,

Statin schützt schon bei normalem LDL-Wert vor Herzinfarkt und Tod  -  Nov 7, 2008
Eine weitere Studie soll schließlich den Stellenwert von Irbesartan bei Herzinsuffizienz belegen. Der Prix Galien International geht in diesem Jahr an den Ärzte Zeitung,

EU Advisory Body Recommends Approval Of Merck KGaA's Kuvan  -  Sep 25, 2008
The Committee adopted a positive opinion for Irbesartan krka (Irbesartan hydrochloride), from Krka dd Novo Mesto, for treatment of essential hypertension CNNMoney.com

Committee for Medicinal Products for Human Use Summary of Positive ...  -  Sep 25, 2008
Irbesartan Krka is a generic of Aprovel which has been authorised in the EU since 27 August 1997. Studies have demonstrated the satisfactory quality of PharmaLive.com (press release),

Intensive Glucose Control in Type 2 Diabetes  -  Oct 1, 2008
...[Medline] Coronel F, Cigarrán S, García-Mena M, Herrero JA, Calvo N, Pérez-Flores I. Irbesartan in hypertensive non-diabetic advanced chronic kidney New England Journal of Medicine (subscription),

Metanalisi sull'effetto dei sartani sulla proteinuria nella ...  -  Aug 18, 2008
Un editoriale di accompagnamento allo studio riporta l’esistenza di un recente studio denominato IMPROVE (Irbesartan in the Management of PROteinuric Pillole.org,

Pharmacopeia Announces Second Quarter 2008 Financial Results  -  Jul 31, 2008
The objective of the Phase 2b study is to evaluate 200 mg and 400 mg of PS433540 versus placebo while also comparing efficacy and safety data to irbesartan. MarketWatch

Pharmacopeia Announces Second Quarter 2008 Financial Results  -  Aug 1, 2008
The objective of the Phase 2b study is to evaluate 200 mg and 400 mg of PS433540 versus placebo while also comparing efficacy and safety data to irbesartan. PharmaLive.com (press release),

College bytes  -  Jul 28, 2008
The research article entitled was Stability Indicating HPTLC method for determination of irbesartan.The research work was done under the guidance of Dr SR Pune Newsline,

Angiotensin-Receptor Blockers Associated With Reduced Incidence of ...  -  Jul 28, 2008
The study included 185906 patients who were taking 1 of 5 different angiotensin-receptor blockers (candesartan, irbesartan, telmisartan, losartan, DG News

Dementia: Blood pressure drugs may cut risk of Alzheimer's by 40%  -  Jul 27, 2008
The most common ARBs are marketed as candesartan, losartan and irbesartan. Wolozin, who is due to announce details of the study at the international guardian.co.uk,

Nem zörög a haraszt: eladás előtt a gyógyszeripari óriás?  -  Jul 30, 2008
2012-ben ugyanis két termékének szabadalmi oltalma is lejár: az egyik az Avapro (vérnyomáscsökkentő, hatóanyag: irbesartan) a másik a Plavix (vérhígító, Weborvos,

Nephropathie: Gefahr fürs Diabetiker-Herz  -  Jul 17, 2008
Zum Nieren-Schutz ist für ACE-Hemmer (Captopril, Lisinopril, Enalapril und Perindopril) sowie für einige Sartane (Irbesartan, Losartan, Telmisartan und Ärzte Zeitung,

Brand Names/Synonyms:
Irbesartan is also known by the following brand names and/or synonymsAvalide; Avapro; CHEMBANK1635; Irbesarran; Irbesartan; Irbesartan [Usan:Inn]; Lrbesartan

Drug Category:
Irbesartan is categorized under the following by the FDA: Antihypertensive Agents; Angiotensin II Receptor Antagonists; ATC:C09CA04

Dosage Forms:
Oral tablets

Absorption:
60-80%

Interactions:
-->Interactions for Irbesartan:

No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.

In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine. However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible. Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isozymes 1A1, 1A2,2A6,2B6,2D6,2E1,or 3A4.

In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin. The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.

Chemical IUPAC Name:
3-butyl-2-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-2,4-diazaspiro[4.4]non-3-en-1-one

:

Web health.mongabay.com/health

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com/health lead to other sites. health.mongabay.com/health does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com/health responsible for dead or misdirected links.